EcoDrugPlus

60s Ribosomal Protein L39-Like

Ensembl ID : ENSDORG00000027725
Gene Symbol: LOC105992402
3 Cross references
112 Possible Orthologues:

A-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSDORG00000001019
Gene Symbol: ARAF
4 Cross references
192 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSDORG00000014267
Gene Symbol: ADAM17
4 Cross references
283 Possible Orthologues:

Adam Metallopeptidase With Thrombospondin Type 1 Motif 5

Ensembl ID : ENSDORG00000015009
Gene Symbol: ADAMTS5
3 Cross references
199 Possible Orthologues:

Akt Serine/threonine Kinase 2

Ensembl ID : ENSDORG00000003591
Gene Symbol: AKT2
4 Cross references
256 Possible Orthologues:

Akt Serine/threonine Kinase 3

Ensembl ID : ENSDORG00000004303
Gene Symbol: AKT3
4 Cross references
202 Possible Orthologues:

Alk Receptor Tyrosine Kinase

Ensembl ID : ENSDORG00000013694
Gene Symbol: ALK
3 Cross references
195 Possible Orthologues:

Atp Binding Cassette Subfamily B Member 1

Ensembl ID : ENSDORG00000010840
Gene Symbol: ABCB1
2 Cross references
160 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 1

Ensembl ID : ENSDORG00000024925
Gene Symbol: ABCC1
3 Cross references
203 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 8

Ensembl ID : ENSDORG00000009602
Gene Symbol: ABCC8
3 Cross references
245 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 9

Ensembl ID : ENSDORG00000026375
Gene Symbol: ABCC9
3 Cross references
233 Possible Orthologues:

Atpase H+/k+ Transporting Subunit Alpha

Ensembl ID : ENSDORG00000000792
Gene Symbol: ATP4A
4 Cross references
183 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).